Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX2-73 for the Treatment of Parkinson’s Disease Dementia

Anavex Life Sciences (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, today announced that the Company has received approval from the Spanish Agency for Medicinal Products and Medical Devices (AEMPS), to initiate its Phase 2, double-blind, placebo-controlled 14-week trial of the safety and efficacy of ANAVEX^®2-73 for the treatment of Parkinson’s disease dementia (PDD).

As quoted in the press release:

Professor Dag Aarsland, MD, Head of Department of Old Age Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience at King’s College London commented: “Since as many as 80 percent of people with Parkinson’s will experience Parkinson’s disease dementia and treatment options are limited, this study is using the latest generation of diagnostic and treatment developments in Parkinson’s disease dementia and I am looking forward to a potential contribution to the future development of this significant unmet need.”

The Company ‘s trial design for the Phase 2 program in PDD includes genomic, precision medicine-based biomarkers identified from patients previously treated with ANAVEX^®2-73. This novel approach has informed clinical trial designs and is expected to yield insight as to potential responders, and to enrich future regulatory submissions.

Click here to read the full press release.